Glaxosmithkline Pharma Peer Comparison
NSE: GLAXO | BSE: 500660
₹2,727.60
As on 20-Nov-2026 15:31IST
Market cap
₹45,841 Cr
Revenue (TTM)
₹4,159 Cr
P/E Ratio
40
P/B Ratio
24.4
Div. Yield
2.1 %
| Glaxosmithkline Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Mankind Pharma | Aurobindo Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
45,841 | 1,20,099 | 1,16,307 | 1,09,653 | 1,03,732 |
Revenue (₹ Cr) |
4,159 | 30,378 | 33,097 | 15,379 | 36,913 |
Net Profit (₹ Cr) |
1,146.54 | 4,159.00 | 2,759.70 | 2,249.69 | 3,993.05 |
Net Margin (%) |
26.40 | 13.20 | 8.03 | 14.32 | 10.61 |
RoE (%) |
54.63 | 16.61 | 7.30 | 13.86 | 10.51 |
Price to Earnings |
39.98 | 28.73 | 41.54 | 48.89 | 26.00 |
Price-To-Book |
24.37 | 4.32 | 3.00 | 6.24 | 2.63 |
Income Statement (₹ Cr)
| Glaxosmithkline Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Mankind Pharma | Aurobindo Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4,158.57 | 30,378.10 | 33,097.40 | 15,378.58 | 36,912.88 |
|
Total Income
|
4,343.18 | 31,504.60 | 34,352.50 | 15,705.47 | 37,650.01 |
|
Total Expenditure
|
2,738.73 | 22,828.30 | 28,236.90 | 11,301.83 | 29,349.95 |
|
EBITDA
|
1,419.84 | 7,549.80 | 4,860.50 | 4,076.75 | 7,562.93 |
|
Depreciation
|
64.35 | 2,027.20 | 2,141.40 | 907.11 | 1,961.27 |
|
EBIT
|
1,355.49 | 5,522.60 | 2,719.10 | 3,169.64 | 5,601.66 |
|
Interest
|
3.26 | 595.90 | 450.40 | 513.87 | 394.85 |
|
Other Income
|
184.61 | 1,126.50 | 1,255.10 | 326.89 | 737.13 |
|
Exceptional Items
|
17.98 | -499.30 | 0.00 | -129.75 | -105.51 |
|
Profit before Tax
|
1,554.82 | 5,553.90 | 3,523.80 | 2,852.91 | 5,838.43 |
|
Provision for Tax
|
408.28 | 1,394.90 | 764.10 | 603.22 | 1,845.38 |
|
Profit after Tax
|
1,146.54 | 4,159.00 | 2,759.70 | 2,249.69 | 3,993.05 |
Liabilities (₹ Cr)
| Glaxosmithkline Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Mankind Pharma | Aurobindo Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,881.05 | 27,817.30 | 38,807.00 | 17,582.22 | 39,399.90 |
|
Minority Interest
|
0.00 | -101.90 | 40.20 | -20.87 | 3.68 |
|
Non-Current Liabilities
|
281.75 | 7,260.60 | 3,074.90 | 5,214.33 | 2,689.12 |
|
Current Liabilities
|
1,805.78 | 18,023.50 | 15,430.30 | 5,884.79 | 19,667.17 |
|
Total Liabilities
|
4,323.87 | 50,672.60 | 56,576.70 | 27,754.83 | 58,196.15 |
Assets (₹ Cr)
| Glaxosmithkline Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Mankind Pharma | Aurobindo Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
420.16 | 36,142.90 | 26,891.10 | 20,096.89 | 26,331.59 |
|
Current Assets
|
3,230.14 | 18,433.50 | 29,732.20 | 7,956.27 | 33,958.66 |
|
Total Assets
|
4,323.87 | 50,672.60 | 56,576.70 | 27,754.83 | 58,196.15 |
|
Total Debt*
|
0.00 | 11,769.50 | 7,734.10 | 6,021.78 | 7,676.20 |
|
Net Current Assets
|
1,424.36 | 410.00 | 14,301.90 | 2,071.48 | 14,291.49 |
|
Contingent Liabilities
|
515.18 | 989.90 | 336.14 | 924.77 | 1,358.37 |
Cashflow (₹ Cr)
| Glaxosmithkline Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Mankind Pharma | Aurobindo Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
903.30 | 2,116.60 | 5,673.70 | 3,121.29 | 5,526.37 |
|
Cash Flow from Investing Activities
|
396.98 | -8,296.10 | -6,549.30 | -196.42 | -3,458.61 |
|
Cash from Financing Activities
|
-737.08 | 5,806.90 | 829.00 | -2,952.69 | -1,269.15 |
|
Net Cash Inflow / Outflow
|
563.20 | -372.60 | -46.60 | -27.82 | 798.61 |
Ratios
Profitability Ratios
| Glaxosmithkline Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Mankind Pharma | Aurobindo Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
66.79 | 21.39 | 13.75 | 13.24 | 12.76 |
|
ROE (%)
|
54.63 | 16.61 | 7.30 | 13.86 | 10.51 |
|
ROA (%)
|
30.04 | 8.11 | 4.93 | 7.79 | 6.99 |
|
EBIT Margin (%)
|
32.60 | 18.18 | 8.22 | 20.61 | 15.18 |
|
Net Margin (%)
|
26.40 | 13.20 | 8.03 | 14.32 | 10.61 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Glaxosmithkline Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Mankind Pharma | Aurobindo Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
12.12 | 24.02 | -3.53 | 13.53 | 13.53 |
|
EBIT Growth (%)
|
18.32 | -16.48 | -58.47 | 31.59 | 13.09 |
|
Net Profit Growth (%)
|
20.03 | -16.41 | -51.77 | 27.79 | 15.82 |
|
EPS Growth (%)
|
18.87 | -10.25 | -51.50 | 34.22 | 19.29 |
|
Book Value Growth (%)
|
16.12 | 13.19 | 12.99 | 13.74 | 16.04 |
Valuation Ratios
| Glaxosmithkline Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Mankind Pharma | Aurobindo Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
40.58 | 26.37 | 41.67 | 46.25 | 25.71 |
|
Price / Book Value
|
24.45 | 4.30 | 3.01 | 6.18 | 2.64 |
|
Dividend Yield (%)
|
2.10 | 0.08 | 0.57 | 0.04 | 0.22 |
|
EV/EBITDA
|
30.43 | 16.46 | 24.17 | 27.63 | 13.36 |
|
Market Cap (₹ Cr)
|
38,682.23 | 87,643.18 | 1,04,763.81 | 82,801.75 | 75,689.14 |
Solvency Ratios
| Glaxosmithkline Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Mankind Pharma | Aurobindo Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.15 | 0.00 | 0.17 | 0.02 |
|
Short term debt to equity ratio
|
-- | 0.16 | 0.16 | 0.04 | 0.16 |
|
Current Ratio
|
1.79 | 1.02 | 1.93 | 1.35 | 1.73 |
|
Quick Ratio
|
1.48 | 0.64 | 1.40 | 0.95 | 1.06 |
|
Interest Coverage
|
477.94 | 10.32 | 8.82 | 6.55 | 15.79 |
Operating Efficiency Ratios
| Glaxosmithkline Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Mankind Pharma | Aurobindo Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
8.16 | 14.42 | 30.64 | 14.17 | 20.44 |
|
Asset Turnover
|
1.09 | 0.59 | 0.59 | 0.53 | 0.65 |
|
Receivable days
|
24.45 | 33.55 | 103.79 | 39.93 | 33.71 |
|
Inventory Days
|
40.60 | 33.80 | 79.94 | 51.78 | 59.32 |
|
Payable days
|
172.70 | 149.82 | 84.78 | 111.46 | 148.20 |
|
Cash Conversion Cycle
|
-107.65 | -82.46 | 98.95 | -19.75 | -55.17 |